Evaluation the Effect of Coenzyme Q10 on Tissue Healing Process in Patients Undergoing Wisdom Tooth Extraction
Launched by ZAHRA NEJATI · Jun 9, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a supplement called Coenzyme Q10 on healing after wisdom tooth extraction. The researchers want to find out if taking Coenzyme Q10 can help patients heal better, reduce the chances of developing a painful condition called dry socket, and prevent issues with jaw movement during recovery. To do this, they will compare Coenzyme Q10 to a placebo, which looks like the supplement but doesn’t contain any active ingredients.
To participate in this study, you need to be over 18 years old and scheduled for wisdom tooth extraction. If you join, you will take 100 mg of Coenzyme Q10 daily for 30 days after your surgery. Researchers will follow up with you at different points—1, 7, 14, and 30 days after your surgery—to see how you're healing. It's important to know that this trial isn’t recruiting participants yet, and certain conditions like being sensitive to Coenzyme Q10 or needing to leave the study for personal reasons may disqualify you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 18 years old that require mandibular or maxillary molar, third tooth extraction as Oral and Maxillofacial surgeon's clinical diagnosis.
- Exclusion Criteria:
- • The patient's departure from Sanandaj
- • The patient's disagreement with the study protocol
- • The Patient's demise
- • The patient's hospitalization for unrelated illnesses
- • The patient's discontent with the care they received
- • The patient's failure to show up for follow-up appointments
- • The patient's sensitivity to Coenzyme Q10
About Zahra Nejati
Zahra Nejati is a distinguished clinical trial sponsor dedicated to advancing medical research and therapeutic innovation. With a strong focus on ethical practices and patient safety, Zahra Nejati collaborates with leading research institutions and healthcare professionals to design and conduct rigorous clinical studies. The organization is committed to generating high-quality data that contributes to the development of effective treatments across various therapeutic areas. Through a patient-centered approach and a robust understanding of regulatory requirements, Zahra Nejati aims to facilitate the translation of scientific discoveries into meaningful healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Zahra Nejati
Study Director
Zahra Nejati, Department of oral and maxillofacial medicine, School of Dentistry, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported